Furthermore, triclabendazole and its metabolites can inhibit ABCG2/BCRP, an ATP-binding cassette transporter that extrudes compounds from cells in the intestine, liver, kidney, and gland, affecting pharmacokinetics of anti-cancer drugs (Barrera et al., 2012). The gene discussed is ABCG2; the disease is cancer.